Members of the
The humoral (antibody) and cellular (T-lymphocyte) responses represent two distinct pathways by which the immune system recognizes and combats viral infections (reviewed in reference 30). Antibodies primarily recognize viruses or viral antigens circulating in the blood and other fluids, whereas T lymphocytes interact with viral antigens in the form of processed peptides bound to host cells and presented in a groove between the two ␣-helices of the major histocompatibility complex (MHC) glycoproteins (3) . Cytotoxic T lymphocytes (CTLs), most of which bear the CD8 molecule, recognize and interact with infected cells that express viral antigen (peptide) presented by MHC class I molecules. Observations of humans and mice with genetic or acquired deficiencies in antibody or T-cell production and experimentally manipulated animals clearly show that control of most acute viral infections is critically dependent on MHC class I-restricted CD8 CTLs (reviewed in reference 30). However, immune clearance of persistent viral infections, in addition to dependence on CD8 CTLs, also requires the participation of CD4 T cells (2, 8, 12, 16, 29) .
CTL responses to infection with the arenaviruses lymphocytic choriomeningitis virus (LCMV) and, likely, Lassa fever virus (LFV) essentially rely on cell-mediated CD8 CTL responses (reviewed in references 6, 29, 30, and 34) . Features of interactions between arenavirus peptides and MHC class I molecules have been delineated molecularly and structurally by biochemical characterization of the naturally presented peptides (10, 11, 13, 19, 32, 33) and analysis of CTLs as viral escape variants (9, 14, 15, 22) . Studies with these and other viruses whose peptides were isolated by elution from MHC class I molecules led to the identification of allele-specific anchor residues within the peptide sequence (reviewed in ref- erence 23) . Similarly, the impact of structural factors at nonanchoring residues in peptide-MHC interactions has been identified by using single amino acid mutations of viral gene products (9, 10) . The nucleoprotein (NP) sequence of LCMV consisting of amino acids (aa) 118 to 126 (NP 118-126) (RPQASGVYM) was found to be L d restricted and to constitute Ͼ97% of the total clonal or total bulk primary CTL responses (32 (10, 11, 13-15, 20, 32, 33) . Gentamicin (400 g/ml) was added to Iscove's modified Dulbecco's medium to maintain selection of T2-L d cells. The LCMV Armstrong clone 53b (LCMV ARM) was used at an MOI of 1 to infect cells. The origin, cloning, sequencing, plaque purification, and quantification of LCMV on Vero cells, expression of viral NP or glycoprotein (GP), and their identification with NP-or GP-specific monoclonal antibodies have been described previously (10, 14, 15, 32) . Details describing the construction and use of recombinant VV expressing full-length LCMV ARM GP, NP, or NP epitope aa 118 to 127 have been published (14, 15, 31, 32) .
Peptides. Peptides were synthesized by the solid-phase method using the N-9-fluorenyl(methylcarbonyl) (Fmoc) chemistry, purified by high-pressure liquid chromatography on a RP300-C8 reverse-phase column (Brownlee lab), and identified by fast atom bombardment or electrospray mass spectrometry (10, 20 Generation and detection of CTLs. Primary LCMV-specific CTLs were generated by priming mice intraperitoneally with 10 5 PFU of LCMV ARM. Spleens from such mice were removed 7 days after inoculation, and single-cell suspensions of spleens (free from erythrocytes) were prepared in complete RPMI 1640 media as described previously (14, 15, 29, 31, 32) . These cells were then tested for their ability to lyse virus-infected or peptide-coated targets as reported previously (14, 15, 24, 29, 31, 32) . The L d -restricted CTL clone HD-8 has been described, and its specificities have been recorded (32) .
A standard 5-to 6-h 51 Cr-release assay (14, 15, 24, 31, 33) was used to measure CTL activity. Target cells were infected with LCMV ARM at an MOI of 1, 48 h before the assay, or with recombinant VV at an MOI of 3, 16 h before the assay. Peptides at various concentrations were used to coat uninfected target cells. The percent specific lysis was calculated as 100[(CPM release by CTL Ϫ CPM of spontaneous release)/(CPM of total release Ϫ CPM of spontaneous release)].
Intracellular cytokine assays were done on BALB spleen cells obtained 7 days after infection with LCMV ARM. Lymphocytes were harvested as described above, restimulated for 5 h in the presence of the indicated arenavirus peptides (0.1 g/ml) plus recombinant human interleukin 2 (50 U/ml) and brefeldin A (1 g/ml), and subsequently stained for CD8, gamma interferon (IFN-␥), and tumor necrosis factor alpha (TNF-␣) as described previously (2, 24) .
RESULTS AND DISCUSSION

The L d MHC CD8
؉ CTL-restricted peptide sequence was remarkably similar among diverse arenaviruses. The L d MHC molecule bound viral peptides via an MHC anchor of proline (P) at P2 and a methionine (M), phenylalanine (F), leucine (L), or isoleucine (I) at P9 or P10 according to elution, alignment, and immunochemical studies (23) . Others (9) employing limited single-amino-acid substitution analysis reported that replacing the authentic P at P2 with an alanine (A) or arginine (R), S at P5 with asparagine (N), or M at P9 with a lysine (K) or L diminished or abolished the capacity of NP peptide to increase cell surface L d expression and to induce L d stabilization in L cells (H-2 k ) manipulated to express L d molecules. In addition, crystallographic analysis of the L d MHC molecule suggested that P3 may also act as an auxiliary MHC anchor with P4 and P8 forming contacts for the CD8 ϩ -T-cell receptor (1, 26) . With the L d -restricted LCMV ARM immunodominant CTL epitope RPQASGVYM (32) used as a guide, the corresponding NP sequences of several Old World and New World arenaviruses were obtained. As shown in Table 1 , NP 118-126 of the Old World LFVs Nigeria (G) and Josiah (J) as well as Mopeia virus shared from 6 to 7 aa with the LCMV ARM peptide. These viruses bore homology to the MHC binding anchor of a P at P2 and an M at P9 but not the suggested P3 auxiliary MHC anchor LCMV ARM (Q), LFV (G and J), and Mopeia (L) residues. As anticipated, L d -expressing cells bound tightly at concentrations of 4 M for Mopeia virus, 20 M for LFV (G), and 5 M for LFV (J) (Table 1; Fig. 1 ). In contrast, the corresponding aligned NP sequence from the New World arenaviruses had less homology to the LCMV prototype, i.e., 2 to 4 aa were shared with the 9 aa residues of LCMV ARM. Further, as shown in Table 1 , none of the New World arenaviruses, Junin, Machupo, Sabia, Pichinde, Oliveros, or Tacaribe, had a P in P2 or a Q or L in P3, although Junin, Machupo, Sabia, and Tacaribe viruses had the correct amino acids to serve as an MHC anchor in P9. Therefore, it was surprising that Sabia bound well to the L d molecules (30 M [ Table 1 and Fig. 1 ], and in a separate experiment, 10 M [ Table 2 ]). Sequence comparison showed that Machupo virus, a nonbinder (affinity of good binders is less than 50 M), and Sabia virus, a good binder, shared serine (S) in P2 but differed with respect to amino acids in P3; Sabia virus had an alanine (A), and Machupo virus had a glycine (G). Further, Sabia virus, like the Old World viruses, had an arginine (R) in P1, whereas Machupo virus had a glutamic acid (E) in that position. To evaluate the role of P at P2 and E at P1 in binding to L d , we substituted E for R in LCMV ARM at P1 and R for E in Machupo virus at the same amino acid residue. LCMV ARM NP 118-126 R P Q A S G V Y M 9/9 (100) 0.5 Ϯ 0.4 (Table 3) , indicating a lack of cross-reactivity by LCMV to the CTL peptide epitope of the New World Sabia virus.
In addition to lysis of infected or peptide-coated target cells, CTLs exhibit effector activity by release of cytokines, such as IFN-␥ or TNF-␣ (reviewed in references 7 and 30). To assay the efficiency of arenavirus peptides in stimulating cytokine production by LCMV ARM-specific CD8 ϩ T cells, IFN-␥-or TNF-␣-producing cells were quantitated. As Fig. 2 demon- strates, of the viruses tested, only LCMV ARM, Mopeia virus, and LFV (only data for LFV [J] shown) peptides specifically stimulated LCMV-specific CD8 ϩ T cells to make the cytokines, but the Sabia virus peptide was unable to. In agreement with the extent of lysis by HD-8 CTLs, CTL accumulation of IFN-␥ or TNF-␣ was enhanced with the Mopeia peptide over that with the corresponding LFV peptide. Sequence comparison suggested that the G in P5 in Sabia virus, compared to S or A at that position among Old World arenaviruses, or the change from V in P7 in Old World arenaviruses to Y in Sabia virus, prevented LCMV ARM CTL recognition. To test for these various possibilities, single-amino-acid mutations were made at positions P4 and P7 and at some other regions in LCMV ARM-and Sabia L d -restricted peptides. As shown in Table 4 , while change of V to Y or vice versa at P7 failed to alter CTL lysis, the change at P5 from S to G or vice versa did allow LCMV ARM CTLs to lyse L d targets coated with Sabia virus mutant peptide. From these data we conclude that the amino acid S in P5 is a T-cell-receptor contact residue that tolerates an A mutation (see Mopeia virus and LFV sequences, Table 3 ), while a G mutation prevents CTL-mediated lysis. We then made a mutation in P3 of Sabia changing the A to G, the residue in the non-L d -binding Machupo virus peptide. The Sabia virus peptide (G in P3 and S in P5) was about half as efficient in preparing the target cell for lysis by LCMV-specific CTLs as Sabia virus peptides with A or Q in P3 and S in P5. These data suggest that ancillary MHC binding occurs via A in P3 of Sabia virus.
In conclusion, CTLs generated in H-2 d BALB mice against LCMV ARM cross-react with NP 118-126 sequences of other Old World arenaviruses. These cross-reactive CTLs efficiently lyse both Mopeia virus and LFV peptide-coated target cells presented by L d MHC molecules and express the antiviral effector cytokines IFN-␥ and TNF-␣. In contrast, no CTL cross-reactivity was evident between Old World and New World arenaviruses with respect to either lytic or cytokine activity. Cumulatively, our results suggest the possibility of a single vaccine for Old World arenaviruses and argue against attempting to use one vaccine to protect against both Old World and New World arenaviruses. The initial classification of Arenaviridae into Old World and New World viruses on the basis of complement-fixing antibody differences before the age of molecular biology appears more justified as sequence information emerges. Further, the observation of cross-CTL recognition among the Old World arenaviruses studied here, but not with the New World arenaviruses, supports this classification. Our data stress two points. First, the CTL commonality shown here among Old World arenaviruses may signify that the sharing of their epitopes among several human HLA motifs would permit the design of a universal vaccine for Old World arenaviruses. Studies to test this possibility are currently under way utilizing sequences for various motif patterns and humanized transgenic mice (28) . Second, the arenaviruses used here may have originated from geographically separate sources and could reflect differences between their natural rodent hosts on each continent. Alphadystroglycan has recently been identified as the receptor for LCMV and LFV (4) . Interestingly, recent studies of binding of arenaviruses to this receptor (S. Kunz, C. Spiropoulou, and M. B. A. Oldstone, unpublished data) indicate that the Old World arenaviruses tested (LFV, Mopeia virus, Mobala virus, and LCMV) all bind with high affinity to this receptor, while in contrast the majority of New World arenaviruses bind with an affinity that is 2 to 3 logs lower. The exception is the clan containing the Oliveros and Latino New World arenaviruses, which bind at high affinity to alpha-dystroglycan.
Studies on vaccination to control LFV infection in rodents have shown that GP and NP vaccines are both effective (5, 17) . However, in subhuman primates, both components of LFV GP (GP1 plus GP2) were required for a protective vaccine; neither LFV NP, GP1, nor GP2 alone was effective (6) . However, new studies in which vaccination successfully protected nonhuman primates from Ebola virus (27) stressed the need of a uniquely designed vaccine protocol to achieve optimal results. Until such approaches are undertaken for LFV and until data concerning LFV-specific T cells becomes available from human or animal models, the roles for various components of the immune response against the viral GP and/or NP remains uncertain. c Effector-to-target ratios are shown in parentheses.
